Skye Bioscience, Inc. (SKYE)
Healthcare
Biotechnology
0.57 $
-2.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Skye Bioscience, Inc. (SKYE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.4% of the shares are freely tradable; institutional investors hold 46.0%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
46.0%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
65.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
3.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
35Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| 5AM Venture Management, LLC | 27.56 | 9,681,763 | +0.0 | 03/31/2026 |
| Versant Venture Management LLC | 5.72 | 2,007,704 | +0.0 | 03/31/2026 |
| Baker Bros Advisors LP | 4.48 | 1,575,243 | +8.6 | 03/31/2026 |
| Vanguard Group Inc | 2.51 | 882,785 | +0.0 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.18 | 764,457 | +0.0 | 03/31/2026 |
| Sphera Funds Management Ltd. | 1.93 | 678,928 | +41.8 | 03/31/2026 |
| BlackRock Inc | 0.81 | 286,131 | +1.5 | 03/31/2026 |
| Geode Capital Management, LLC | 0.79 | 277,256 | +31.9 | 03/31/2026 |
| Millennium Management LLC | 0.74 | 258,200 | -32.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.60 | 561,832 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.